ABBV 969
Alternative Names: ABBV-969Latest Information Update: 05 Apr 2024
At a glance
- Originator AbbVie
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action STEAP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 08 Mar 2024 Phase-I clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Monotherapy) in USA (IV) (NCT06318273)
- 30 Nov 2023 Preclinical trials in Prostate cancer in USA (IV) prior to November 2023
- 30 Nov 2023 AbbVie plans to submit IND application for ABBV 969 in Prostate cancer in December 2023